209 related articles for article (PubMed ID: 6234371)
1. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
Dye ES; North RJ
J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
[TBL] [Abstract][Full Text] [Related]
2. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.
Dye ES; North RJ
J Exp Med; 1981 Oct; 154(4):1033-42. PubMed ID: 6457075
[TBL] [Abstract][Full Text] [Related]
3. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.
Awwad M; North RJ
J Exp Med; 1988 Dec; 168(6):2193-206. PubMed ID: 2974065
[TBL] [Abstract][Full Text] [Related]
4. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells.
Mills CD; North RJ
J Exp Med; 1983 May; 157(5):1448-60. PubMed ID: 6189937
[TBL] [Abstract][Full Text] [Related]
5. In vitro expression of secondary antitumor immunity by in vitro tumor-sensitized T cells: inhibition by tumor-induced suppressor T cells.
Kaymakcalan Z; Spitalny GL; Bursuker I
Cancer Immunol Immunother; 1987; 25(2):69-74. PubMed ID: 2959361
[TBL] [Abstract][Full Text] [Related]
6. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
Hines DL
Cancer Immunol Immunother; 1989; 28(4):241-7. PubMed ID: 2495177
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity.
North RJ; Neubauer RH; Huang JJ; Newton RC; Loveless SE
J Exp Med; 1988 Dec; 168(6):2031-43. PubMed ID: 3143799
[TBL] [Abstract][Full Text] [Related]
8. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
Dye ES
J Immunol; 1986 Feb; 136(4):1510-5. PubMed ID: 3080526
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.
Awwad M; North RJ
Immunology; 1988 Sep; 65(1):87-92. PubMed ID: 2972604
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of established tumors. Acquisition of radioresistance by tumor-specific T cells after passive transfer into tumor-bearing recipients.
Dunn PL; North RJ
Int J Cancer; 1994 May; 57(4):592-7. PubMed ID: 8181862
[TBL] [Abstract][Full Text] [Related]
11. Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.
North RJ; Dye ES
Immunology; 1985 Jan; 54(1):47-56. PubMed ID: 3156088
[TBL] [Abstract][Full Text] [Related]
12. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.
North RJ
Cancer Immunol Immunother; 1984; 16(3):175-81. PubMed ID: 6231095
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of Nocardia rubra cell wall skeleton on syngeneically transplanted P388 tumors.
Izumi S; Ogawa T; Miyauchi M; Fujie K; Okuhara M; Kohsaka M
Cancer Res; 1991 Aug; 51(15):4038-44. PubMed ID: 1855218
[TBL] [Abstract][Full Text] [Related]
14. Elimination of L5178Y cells from tumor-dormant DBA/2 mice by specific active immunotherapy.
Marsili MA; Robinson MK; Truitt GA; Wheelock EF
Cancer Res; 1983 Jan; 43(1):15-21. PubMed ID: 6600159
[TBL] [Abstract][Full Text] [Related]
15. Progressive growth of immunogenic tumors: relationship between susceptibility of ascites P815 tumor cells to T-cell-mediated lysis and immune destruction in vivo.
Fahey JR; Hines DL
Cancer Res; 1987 Sep; 47(18):4759-65. PubMed ID: 3113723
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.
Inge TH; Hoover SK; Frank JL; Kawabata TT; Bethke KP; Bear HD
Cancer Immunol Immunother; 1992; 35(2):119-26. PubMed ID: 1534514
[TBL] [Abstract][Full Text] [Related]
17. A role for mast cells and the vasoactive amine serotonin in T cell-dependent immunity to tumors.
Van Loveren H; Den Otter W; Meade R; Terheggen PM; Askenase PW
J Immunol; 1985 Feb; 134(2):1292-9. PubMed ID: 3871209
[TBL] [Abstract][Full Text] [Related]
18. Anti-estrogens potentiate the immunotherapy of the P815 murine mastocytoma by cytotoxic T lymphocytes.
Nagy E; Baral E; Kangas L; Berczi I
Anticancer Res; 1997; 17(2A):1083-8. PubMed ID: 9137453
[TBL] [Abstract][Full Text] [Related]
19. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells.
Rakhmilevich AL; North RJ; Dye ES
Int J Cancer; 1993 Sep; 55(2):338-43. PubMed ID: 8103762
[TBL] [Abstract][Full Text] [Related]
20. Immunization of DBA/2 mice with a T cell hybridoma-derived TsF increases immune resistance to the syngeneic tumors P815 and L1210.
Steele JK; Singhai R; Stammers AT; Levy JG
J Immunol; 1986 Nov; 137(9):3025-30. PubMed ID: 3489783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
